Pretherapeutic scalene lymph node biopsy in ovarian cancer

Petru, Edgar; Pickel, H.; Tamussino, Karl; Lahousen, M.; Heydarfadai, M.; Posawetz, W.; Jakse, R

doi:10.1016/0090-8258(91)90032-z

Cited by 15 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the extent of debulking achievable may be directly related to tumour biology, which would strongly bias results from non-RCTs. Tumours that have spread to the para-aortic or scalene lymph nodes may be less likely to be optimally debulked intra-abdominally (Burghardt 1991; Petru 1991). Thus, the ability to achieve successful debulking may reflect tumour biology rather than an independent effect on outcome.…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

Morrison

Haldar

Kehoe

et al. 2012

Cochrane Database of Systematic Reviews

134

View full text Add to dashboard Cite

Background Epithelial ovarian cancer presents at an advanced stage in the majority of women. These women require surgery and chemotherapy for optimal treatment. Conventional treatment is to perform surgery first and then give chemotherapy. However, it is not yet clear whether there are any advantages to using chemotherapy before surgery. Objectives To assess whether there is an advantage to treating women with advanced epithelial ovarian cancer with chemotherapy before cytoreductive surgery (neoadjuvant chemotherapy (NACT)) compared with conventional treatment where chemotherapy follows maximal cytoreductive surgery. Search methods For the original review we searched, the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 3, 2006), MEDLINE (Silver Platter, from 1966 to 1 Sept 2006), EMBASE via Ovid (from 1980 to 1 Sept 2006), CANCERLIT (from 1966 to 1 Sept 2006), PDQ (search for open and closed trials) and MetaRegister (most current search Sept 2006). For this update randomised controlled trials (RCTs) were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 3, 2011) and the Cochrane Gynaecological Cancer Specialised Register (2011), MEDLINE (August week 1, 2011), EMBASE (to week 31, 2011), PDQ (search for open and closed trials) and MetaRegister (August 2011). Selection criteria RCTs of women with advanced epithelial ovarian cancer (Federation of International Gynaecologists and Obstetricians (FIGO) stage III/IV) who were randomly allocated to treatment groups that compared platinum-based chemotherapy before cytoreductive surgery with platinum-based chemotherapy following cytoreductive surgery. Data collection and analysis Data were extracted by two review authors independently, and the quality of included trials was assessed by two review authors independently. Main results One high-quality RCT met the inclusion criteria. This multicentre trial randomised 718 women with stage IIIc/IV ovarian cancer to NACT followed by interval debulking surgery (IDS) or primary debulking surgery (PDS) followed by chemotherapy. There were no significant differences between the study groups with regard to overall survival (OS) (670 women; HR 0.98; 95% CI 0.82 to 1.18) or progression-free survival (PFS) (670 women; HR 1.01; 95% CI 0.86 to 1.17). Significant differences occurred between the NACT and PDS groups with regard to some surgically related serious adverse effects (SAE grade 3/4) including haemorrhage (12 in NACT group vs 23 in PDS group; RR 0.50; 95% CI 0.25 to 0.99), venous thromboembolism (none in NACT group vs eight in PDS group; RR 0.06; 95% CI 0 to 0.98) and infection (five in NACT group vs 25 in PDS group; RR 0.19; 95% CI 0.07 to 0.50). Quality of life (QoL) was reported to be similar for the NACT and PDS groups. Three ongoing RCTs were also identified. Authors’ conclusions We consider the use of NACT in women with stage IIIc/IV ovarian cancer to be a reasonable alternative to PDS, particularly in bulky disease. With regard to selecting who will benefit ...

show abstract

Section: Introductionmentioning

confidence: 99%

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

Morrison

Haldar

Kehoe

et al. 2012

Cochrane Database of Systematic Reviews

134

View full text Add to dashboard Cite

show abstract

“…Microscopic disease was much more common. Positive nodes were found in 7 of 32 patients (22%) with stage III or IV disease who had elective node sampling (67). Nodes are usually associated with pelvic or para-aorti c nodes.…”

Section: Ovarian Carcinomamentioning

confidence: 98%

Metastatic Cervical Lymph Nodes from Urogenital Tract Carcinoma: A Diagnostic and Therapeutic Challenge

Ferlito¹,

Shaha²,

Buckley³

et al. 2001

Acta Oto-Laryngologica

View full text Add to dashboard Cite

“…A similar finding pertains to scalene node metastases. Thirteen out of thirty women with negative nodes had macroscopic clearance of all intra‐abdominal tumour, whereas this was never achieved in node positive women 15 . Although the purpose of these case series was to describe lymph node metastases in ovarian cancer, both demonstrate that tumours with a greater potential for lymphatic metastases reduce the likelihood of optimum resection in women with similar stage disease.…”

mentioning

confidence: 99%

Primary debulking surgery in advanced ovarian carcinoma

Kehoe

1996

BJOG

View full text Add to dashboard Cite

Pretherapeutic scalene lymph node biopsy in ovarian cancer

Cited by 15 publications

References 9 publications

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

Metastatic Cervical Lymph Nodes from Urogenital Tract Carcinoma: A Diagnostic and Therapeutic Challenge

Primary debulking surgery in advanced ovarian carcinoma

Contact Info

Product

Resources

About